Tested treatment for multiple myeloma after standard care
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This Phase 2 study tests a study treatment in adults with multiple myeloma that needs treatment. It may help by trying to improve disease control after you’ve had (or are scheduled to have) standard therapy like chemotherapy and stem cell transplant for some people.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old
- Your overall health/function is good enough (ECOG 0 to 2) at screening and right before treatment
- You have multiple myeloma that needs treatment, with measurable lab markers or criteria showing active disease
- For some study groups: you must be newly diagnosed and have had specific induction therapy and a stem cell transplant within set time windows
- You do NOT have myeloma in the brain or spinal fluid (CNS/meningeal involvement)
- You cannot be on treatments or have conditions that block participation (examples: recent stroke/seizure, certain infections like HIV/hepatitis B/active hepatitis C, pregnancy/breastfeeding)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This phase 3 trial tests two different drug combinations to treat newly diagnosed multiple myeloma. It may help by aiming to control the cancer without using high-dose chemotherapy and stem cell transplant for people who can’t receive that approach.
This trial is testing a new combination of drugs for people with untreated multiple myeloma who are healthy enough for a stem cell transplant. It aims to see if the treatment is safe and effective.
This Phase 2 trial tests two antibody medicines (teclistamab or talquetamab) given as outpatient injections, to treat multiple myeloma. It also tests preventing and treating side effects with supportive medicines, aiming to improve disease control in people who have already tried other myeloma treatments.
This trial tests two drugs (talquetamab and teclistamab) to see if they can eliminate remaining cancer cells in newly diagnosed myeloma patients who have already had a stem cell transplant. It may be an option if you have minimal residual disease (MRD) and a good response to initial treatment.
This trial tests two combinations of drugs (Dara-RVd and Teclistamab-RVd) for people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal is to see if adding a newer drug called Teclistamab improves outcomes.
This trial tests whether adding teclistamab to lenalidomide (or using teclistamab alone) helps keep newly diagnosed multiple myeloma from coming back after an autologous stem cell transplant. It’s comparing these options to lenalidomide alone as long-term maintenance.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.